ライフサイエンスコーパス: extracorporeal life support

1 linical conditions, including surgery and on extracorporeal life support.

2 Venoarterial or venovenous extracorporeal life support.

3 ilation was utilized for 1 to 17 days before extracorporeal life support.

4 nt protocols were followed before and during extracorporeal life support.

5 n infants during early and late venoarterial extracorporeal life support.

6 13 adults undergoing PLV who were receiving extracorporeal life support.

7 eurodevelopmental outcome after venoarterial extracorporeal life support.

8 iratory distress syndrome who were receiving extracorporeal life support.

9 duct use-associated lung injury who received extracorporeal life support.

10 ilation were the most common indications for extracorporeal life support.

11 bilization and, in severe cases, can involve extracorporeal life support.

12 and one patient required multiple rounds of extracorporeal life support.

13 (45%) veno-venous and 12 (55%) veno-arterial extracorporeal life support.

14 ith severe acute chest syndrome managed with extracorporeal life support.

15 return of spontaneous circulation and 22% by extracorporeal life support.

16 timal medical therapy were implanted with an extracorporeal life support.

17 sets of cardiac surgery patients who require extracorporeal life support.

18 th mortality in children who require cardiac extracorporeal life support.

19 penia is a recognized concern in patients on extracorporeal life support.

20 te hospital admission in which they received extracorporeal life support.

21 he sickest neonates, such as those requiring extracorporeal life support.

22 illatory ventilation, prone positioning, and extracorporeal life support.

23 spiratory failure treated with lung rest and extracorporeal life support, a predicted 50% mortality r

24 Bijugular venovenous extracorporeal life support access, a pulmonary artery c

25 linical trials demonstrating the efficacy of extracorporeal life support, adult cardiopulmonary failu

26 ifibrotic therapy, technological advances in extracorporeal life support, advances in understanding o

27 For the first 30 mins on extracorporeal life support, all animals were ventilated

28 ts with severe respiratory failure receiving extracorporeal life support and may be associated with i

29 using a combination of the terms related to extracorporeal life support and organ donation.

30 Patients requiring extracorporeal life support and patients initiated on co

31 kopenia, acute lung injury, vasopressor use, extracorporeal life support, and mortality than either g

32 een patients (93%) were placed on venovenous extracorporeal life support, and one patient required mu

33 mber of hospital days, continued bleeding on extracorporeal life support, and survival.

34 nd the use of recently developed systems for extracorporeal life support are required.

35 a controversial, invasive technique termed 'extracorporeal life support' as a means to provide tempo

36 These data suggest that venovenous extracorporeal life support can be an effective treatmen

37 Extracorporeal life support can lead to rapid reversal o

38 , adjusting for demographics, diagnosis, pre-extracorporeal life support care, extracorporeal life su

39 literature review and by direct contact with extracorporeal life support centers.

40 data were collected via direct contact with extracorporeal life support centers.

41 The extracorporeal life support cohorts were as follows: 1)

42 ), and mortality were evaluated across three extracorporeal life support cohorts.

43 at failed to demonstrate its efficacy, adult extracorporeal life support continues in limited centers

44 l ventilation and adjunctive therapies fail, extracorporeal life support continues to be used as a re

45 ing days and 11% of direct procedure-related extracorporeal life support costs.

46 Extracorporeal life support could be helpful for severe

47 arding presentation, ventilatory management, extracorporeal life support details, and outcome were an

48 Total extracorporeal life support duration ranged from 2 to 37

49 tation was stronger among those who received extracorporeal life support: each extra week of gestatio

50 cardiac catheterization laboratory (CCL) for extracorporeal life support (ECLS) and revascularization

51 Extracorporeal life support (ECLS) as a bridge to lung t

52 Critically ill neonates on extracorporeal life support (ECLS) demonstrate elevated

53 Extracorporeal life support (ECLS) during severe ARDS ma

54 Extracorporeal life support (ECLS) has become increasing

55 An artificial placenta using extracorporeal life support (ECLS) has been investigated

56 al outcomes in bleeding complications during extracorporeal life support (ECLS) have been poorly inve

57 trospectively reviewed their experience with extracorporeal life support (ECLS) in 100 adult patients

58 The University of Michigan experience with extracorporeal life support (ECLS) in 1000 consecutive p

59 Extracorporeal life support (ECLS) is a means of respira

60 The use of methylene blue or extracorporeal life support (ECLS) is also suggested as

61 al circulatory systems (MCSs) in patients on extracorporeal life support (ECLS) is challenging due to

62 Survival after pediatric cardiac extracorporeal life support (ECLS) is guarded, and neuro

63 Extracorporeal life support (ECLS) is increasingly used

64 We hypothesized that extracorporeal life support (ECLS) may be an effective t

65 ermany found that survival after respiratory extracorporeal life support (ECLS) was lower among patie

66 l mortality and (2) death or requirement for extracorporeal life support (ECLS) within 72 hours of ho

67 vous system (CNS) complications of pediatric extracorporeal life support (ECLS).

68 whose gas exchange was partially provided by extracorporeal life support (ECLS).

69 s syndrome of sufficient severity to require extracorporeal life support (ECLS).

70 Its use may decrease the need for extracorporeal life support (ECLS).

71 nhaled nitric oxide, liquid ventilation, and extracorporeal life support (ECLS, ECMO).

72 The aim of this study was to report the extracorporeal life support experience for severe acute

73 The use of extracorporeal life support (extracorporeal membrane oxy

74 In addition, the extracorporeal life support flow rate required to mainta

75 ublication of a randomized clinical trial of extracorporeal life support for acute respiratory failur

76 Clinical trials of extracorporeal life support for acute respiratory failur

77 al growth over the last decade in the use of extracorporeal life support for adults with acute respir

78 Support International Registry who received extracorporeal life support for cardiac support between

79 mortality in pediatric patients who receive extracorporeal life support for cardiac support.

80 atabase of patients temporary implanted with extracorporeal life support for refractory arrhythmic st

81 2 patients with sickle cell disease required extracorporeal life support for severe acute chest syndr

82 Extracorporeal life support for severe ARDS in adults is

83 Venoarterial or venovenous extracorporeal life support for severe pulmonary failure

84 Extracorporeal life support has been implemented since t

85 Extracorporeal life support has been successful in the t

86 The use of pump-driven and pumpless extracorporeal life support has rapidly expanded and all

87 oxygenation therapy with prone ventilation, extracorporeal life support, high-frequency oscillatory

88 ccurred after a median time of 3 hours after extracorporeal life support implantation for the remaini

89 Patients' characteristics and outcomes after extracorporeal life support implantation were analyzed.

90 Nonsurvivors had a higher severity at extracorporeal life support implantation, as assessed by

91 of the recently published ECLS-SHOCK trial (Extracorporeal Life Support in Cardiogenic Shock) and EC

92 duct use-associated lung injury, the role of extracorporeal life support in its management remains un

93 The Extracorporeal Life Support in LT Registry includes data

94 mproves oxygenation and reduces the need for extracorporeal life support in near-term and term newbor

95 acute respiratory failure and (2) the use of extracorporeal life support in patients with severe acut

96 st, the INCEPTION trial (Early Initiation of Extracorporeal Life Support in Refractory Out-of-Hospita

97 The role of extracorporeal life support in the management of adults

98 ized and he required the rapid initiation of extracorporeal life support, in order to achieve hemodyn

99 Interest in extracorporeal life support increased with the confluenc

100 As the evidence supporting the use of extracorporeal life support increases, its indications a

101 intubated for 1.9 days (range, 0-6) prior to extracorporeal life support initiation.

102 all North American pediatric patients in the Extracorporeal Life Support International Registry who r

103 Extracorporeal life support is an invasive technique tha

104 Extracorporeal life support is extraordinary but reasona

105 In the most severe forms of the syndrome, extracorporeal life support is increasingly being deploy

106 Extracorporeal life support is not contraindicated in pa

107 Extracorporeal life support is now an acceptable form of

108 Extracorporeal life support is used for patients with se

109 Extracorporeal life support maintains gas exchange durin

110 ute respiratory distress syndrome, have made extracorporeal life support more widely accepted in clin

111 asurements were made early (< or = 12 hrs of extracorporeal life support, n = 10) or late (> or = 48

112 e support, n = 10) or late (> or = 48 hrs of extracorporeal life support, n = 10).

113 before extracorporeal life support, time on extracorporeal life support, number of ventilator days,

114 ilation, need for renal replacement therapy, extracorporeal life support or cardiopulmonary resuscita

115 -hospital cardiac arrest, immediate need for extracorporeal life support or hemodialysis.

116 with chronic obstructive pulmonary disease, extracorporeal life support or hyperbaric oxygen therapy

117 a previous kidney transplant, were receiving extracorporeal life support or ventricular assist device

118 a composite of low cardiac output syndrome, extracorporeal life support, or death; length of stay in

119 We examined data from the Extracorporeal Life Support Organisation registry to ide

120 MO from 2000 to 2012 were extracted from the Extracorporeal Life Support Organization (ELSO) internat

121 Using the Extracorporeal Life Support Organization (ELSO) registry

122 We used data from the Extracorporeal Life Support Organization (ELSO) Registry

123 The extracorporeal life support organization (ELSO) registry

124 Case reports submitted to the Extracorporeal Life Support Organization and hospital re

125 Early Treatment of Acute Lung Injury and the Extracorporeal Life Support Organization centers were le

126 with a diagnosis of acute myocarditis in the Extracorporeal Life Support Organization database from 1

127 Data reported to Extracorporeal Life Support Organization from 350 intern

128 re from 1989 to 2013 were extracted from the Extracorporeal Life Support Organization international m

129 We examined hyperoxia in the Extracorporeal Life Support Organization Registry among

130 We retrospectively analysed the Extracorporeal Life Support Organization Registry and CO

131 Data from the Extracorporeal Life Support Organization Registry and th

132 Adult patients with CS from the Extracorporeal Life Support Organization Registry betwee

133 Cardiac ECMO runs in adults from the Extracorporeal Life Support Organization Registry betwee

134 Using the Extracorporeal Life Support Organization Registry betwee

135 Extracorporeal Life Support Organization Registry databa

136 The authors queried the Extracorporeal Life Support Organization registry for ad

137 We included Extracorporeal Life Support Organization Registry patien

138 rporeal membrane oxygenation patients in the Extracorporeal Life Support Organization registry, appro

139 tional, retrospective cohort study using the Extracorporeal Life Support Organization Registry, inclu

140 The Extracorporeal Life Support Organization Registry, which

141 ormed a retrospective cohort study using the Extracorporeal Life Support Organization Registry.

142 eal membrane oxygenation and included in the Extracorporeal Life Support Organization registry.

143 data from the International Registry of the Extracorporeal Life Support Organization to identify ris

144 mentaries, and published guidelines from the Extracorporeal Life support Organization were considered

145 run for respiratory failure reported to the Extracorporeal Life Support Organization's data registry

146 Retrospective analysis of the Extracorporeal Life Support Organization's data registry

147 using E-CPR were analyzed with data from the Extracorporeal Life Support Organization, and predictors

148 rporeal Membrane Oxygenation Network and the Extracorporeal Life Support Organization, including cons

149 e recorded prospectively and reported to the Extracorporeal Life Support Organization.

150 ere included, as well as guidelines from the Extracorporeal Life Support Organization.

151 he Society of Critical Care Medicine and the Extracorporeal Life Support Organization.

152 rane oxygenation centers registered with the Extracorporeal Life Support Organization.

153 elated with each other during early and late extracorporeal life support (p = .0001; r2 = .91).

154 thresholds and mortality in three cohorts of extracorporeal life support patients.

155 sary to manage the spectrum of FM, including extracorporeal life support, percutaneous and durable ve

156 Extracorporeal life support provides life support for AR

157 s (50%) eventually died, none of them due to extracorporeal life support-related complications, but m

158 , extracorporeal life support variables, and extracorporeal life support-related complications.

159 Extracorporeal life support seems an efficient therapy f

160 Because extracorporeal life support serves only to supplement ph

161 Adult extracorporeal life support survival rates for respirato

162 Of 7,106 patients undergoing cardiac extracorporeal life support, the majority of patients we

163 led economic evaluation of hospital costs of extracorporeal life support therapy in the Netherlands s

164 rameters and systemic PaO2/FiO2 ratio before extracorporeal life support, time on extracorporeal life

165 imed at analyzing the efficacy and safety of extracorporeal life support to treat refractory arrhythm

166 , or mechanical circulatory devices, such as extracorporeal life support, to facilitate functional re

167 ands showed that mean total hospital cost of extracorporeal life support treatment is euro 106.263 pe

168 oningen in the period 2010-2013 and received extracorporeal life support treatment.

169 life support, adult cardiopulmonary failure extracorporeal life support trials have proved less comp

170 r difference, 0.2-0.4; P < .001), and higher extracorporeal life support use (White: 316 patients [30

171 Veno-arterial extracorporeal life support (VA-ECLS) is widely used to

172 nosis, pre-extracorporeal life support care, extracorporeal life support variables, and extracorporea

173 equent meta-analysis together suggested that extracorporeal life support was beneficial for patients

174 patients were physiologically similar before extracorporeal life support was initiated: shunt of 48 +

175 = 50 torr (</= 6.7 kPa) with an FIO2 of 1.0, extracorporeal life support was instituted.

176 reater than or equal to 21 days, duration of extracorporeal life support was not significantly associ

177 ge, included patients were 36 y old, and the extracorporeal life support was used for 4 d.

178 Extracorporeal life support was utilized in 36 acute res

179 The costs of extracorporeal life support were differentiated in costs

180 Typical lung rest settings during extracorporeal life support were F10(2) of 0.40, peak in

181 rted diagnostic criteria) and were placed on extracorporeal life support were included.

182 multicenter observational study suggest that extracorporeal life support, when combined with lower Vt

183 ed in sickle cell disease patients receiving extracorporeal life support while in severe multiple org

184 The remaining 13 patients (50%) had extracorporeal life support withdrawn after 6.7 +/- 3.6